Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
about
Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceMulticenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumoniaEffect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS MethodSummary of information on human CYP enzymes: human P450 metabolism data.Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Coprescription of tamoxifen and medications that inhibit CYP2D6.Optimizing QSAR models for predicting ligand binding to the drug-metabolizing cytochrome P450 isoenzyme CYP2D6.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Interactions between recreational drugs and antiretroviral agents.Anticonvulsant and antiretroviral interactions.PharmGKB summary: Efavirenz pathway, pharmacokineticsP glycoprotein in human immunodeficiency virus type 1 infection and therapy.Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral TherapyDrug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Current status of antiretroviral therapy.Extracting drug-enzyme relation from literature as evidence for drug drug interactionQuantitative histological assessment of xenobiotic-induced liver enzyme induction and pituitary-thyroid axis stimulation in rats using whole-slide automated image analysis.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Drug interactions in the management of HIV infection: an update.Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Warfarin-antiretroviral interactions.Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal modelsNevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure.Drug interactions with antiretrovirals and warfarin.Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteersHepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.Cortisol serum levels and their relationship to certain antiretroviral drugs.
P2860
Q24628212-63816D5D-73DB-432D-9FCF-D637BFFAD7C5Q27692040-DBBE6D26-C8DC-4432-9AB6-3BA381DCC556Q28542714-66EFFB8E-3E3F-451F-9C11-D55A789C0CB2Q28550189-C4A724E5-66CE-4375-AB15-358E4ED97E92Q32103802-DE0EEE41-D9B9-4829-9BEA-353E1D505E32Q33186873-472D70D6-9E8E-4E63-A07E-3B7BA6604A24Q33797986-52824EE3-2CAD-40DA-BE97-EF4C8A45AD0DQ33821729-879F3306-8729-4B36-8878-2FF3A5AAFEA1Q33898184-43377D27-87D8-4631-A110-053FD8D5FF49Q33901341-D668350F-299A-4FCC-83F6-85432A4DD909Q34430456-6BDC85F4-70B3-4E47-9DF5-C75198BA5232Q34721793-0EF18CD4-CE4F-495E-A777-00A1E145BB08Q34874414-3E6D470F-5DF7-4678-B1F1-25688D0039FEQ35670044-7BCAE4BC-DE12-4F4B-B63F-ABE7DE257303Q35706069-48210D2E-C9A5-4C9B-AACD-389A4EF58DDDQ35718765-39389474-9835-4CF8-B3FF-1863276FBD9BQ35825158-12DC3190-9CB2-40BB-B3FD-662CBBA67CE9Q36080621-5E34EF5C-EFE2-4076-AAAA-0A3E46AD40F6Q36290691-EB4A6575-DCD6-455D-B31F-4D3F67EAC49FQ36362462-C3F3AF02-9A8A-42EE-B3B9-78FC2B04CD30Q36544977-C45357A0-4CAE-42BF-85BB-D5D857E14556Q36548703-EAB40D4D-5550-4784-AD44-307D98DAE3CBQ36657508-B915927C-704C-418A-9449-8AA057C0FF43Q36796304-6D52D934-F2EE-4BBA-BE31-3D8513E76FC3Q36887128-0AC790C6-945E-404D-9A82-C1028E52AE95Q37000733-78D3348D-AC4E-4CD4-87E8-16602568967CQ37086418-BF516074-04C3-4BB9-8487-72E8927513ADQ37364219-EA7DF445-9138-415E-8C21-97BB9BEEB00AQ37378110-D3F602BB-B85F-409B-A489-CE0768063C32Q37386503-4D3BDA9E-B76D-4B38-918E-A6561FD709E3Q37395532-5FBCAD4D-A703-4451-AE8D-3DB3175FD2F5Q37598731-884D3635-0935-4D8F-B110-DFBC1CF5FE52Q37669678-87E69D65-1584-4C6C-950F-C7E8FA8D821EQ37679935-AEAE233A-4F00-4985-8890-94DD23F9A8BAQ37848142-4B622869-029B-4C6E-92A0-BA6CE45372CAQ38920747-EB97B246-284D-4F43-B61A-22BF61558DE3Q42057303-B914FC16-589A-471F-A5C0-737F6D71F776Q42283777-3C6E1D78-27D7-495B-976A-51502822989BQ43851688-E249BAD2-9F24-47AD-A94F-6A90704AC146Q45015735-DE7A7489-35B9-4A8B-A02F-1584F441C887
P2860
Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@ast
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@en
type
label
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@ast
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@en
prefLabel
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@ast
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@en
P2093
P2860
P1476
Inhibition of human cytochrome ...... erse transcriptase inhibitors.
@en
P2093
B W Granda
D J Greenblatt
G M Giancarlo
J S Harmatz
L L von Moltke
R I Shader
P2860
P356
10.1177/00912700122009728
P577
2001-01-01T00:00:00Z